Clinical Gastroenterology and Hepatology

Article	Citations
Editorial Board	541
Front Cover	432
Hepatic Artery Pseudoaneurysm After Whipple Procedure	309
Table of Contents	303
Blue Notes	279
Editorial Board	243
Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study	224
Blue Notes	217
FODMAPs in IBS: Revisiting Restriction	204
Elsewhere in the AGA Journals	195
Reply	192
Editorial Board	187
Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling	186
Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?	179
Gut Microbiome Modulation by Antibiotics in Adult Asthma: A Human Proof-of-Concept Intervention Trial	168
The Evolving Landscape of Colorectal Cancer Screening and Colonoscopy Practice: Insights From the Japan Polyp Study	166
Reply	145
Attribution of Colonoscopy Risk Does Not FIT!	142
Aseptic Abscess Syndrome With Ulcerative Colitis and Pyoderma Gangrenosum	140
Relative Cost-effectiveness of Management Strategies for Uninvestigated Dyspepsia	136
Australasian Insights and Perspectives on the Burden of Chronic Liver Disease	132
Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States	131
Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injury	127
Who Examines the Colon Matters More Than What Is Removed	126
Perianal Disease in Pediatric-onset Crohn’s Disease: Incidence, Disease Course, and Long-term Outcomes	122

Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials	121
High Hospitalization Rates and Risk Factors Among Frail Patients With Cirrhosis: A 10-year Population-based Cohort Study	120
Natural History of Patients Lost to Follow-up After Esophageal Food Impaction	118
Correction	118
Table of Contents	114
Barrett’s Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study	114
Overall and Annual Postcolonoscopy Colorectal Cancer Rates in a Large Integrated Healthcare Setting: A Cross-Sectional Study	111
Disaggregating Racial and Ethnic Data: A Step Toward Diversity, Equity, and Inclusion	111
Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis: Holding Out for a Superdonor?	110
Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial	108
Low Daily Step Count Is Associated With a High Risk of Hospital Admission and Death in Community-Dwelling Patients With Cirrhosis	108
Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist	106
Frequent Abnormal Pancreas Imaging in Patients With Pathogenic ATM, BRCA1, BRCA2, and PALB2 Breast Cancer Susceptibility Variants	105
A Novel, Noninvasive Method to Diagnose Active Eosinophilic Esophagitis, Combining Clinical Data and Oral Cavity RNA Levels	102
Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population	99
Fecal Microbiota-based Therapies Compared to Fecal Microbiota Transplantation for Preventing Recurrent C. difficile Infection	97
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis	96
Development of a Simple, Point-of-Care Device to Test Anorectal Function in Patients with Constipation: Randomized Clinical Trial	96
Assessment and Significance of Histologic Activity in Crohn’s Disease	93
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease	92
Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient in Clinical Practice: An Investigational Procedure—What Can We Tell Patients?	91
PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission	90
The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy	87
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis	87
Symptom-Based Testing and Eradication of Helicobacter pylori and Risk of Gastric Cancer	87
Hepatic Steatosis Is Associated With Increased Cardiovascular Risk Through Adverse Coronary Plaque Composition	86
Association of Statin Usage and the Development of Diabetes Mellitus after Acute Pancreatitis	86
Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease	86
Health Disparities in Inflammatory Bowel Disease Care Driven by Rural Versus Urban Residence: Challenges and Potential Solutions	86
Daily or Twice Daily Treatment With Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis	85
An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States	85
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment	84
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA	83
Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study	83
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary	81
AI-Assisted Capsule Endoscopy for Detection of Ulcers and Erosions in Crohn’s Disease: A Multicenter Validation Study	80
Ambulatory Acute Kidney Injury in Patients With Cirrhosis Is Common and Burdensome	79
Fecal Immunochemical Tests: The Right Colorectal Cancer Screening Test for the Average-Risk Population?	79
Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease	78
AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review	78
Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study	78
Associations Between Sexual Orientation and Disorders of Gut-Brain Interaction in Sexual Minority Populations	77
Hypermobile Ehlers-Danlos Syndrome and the Nosology of Disorders of Gut-Brain Interaction	77
Reply	77
Front Cover	77
Prevalence of Gastric Precursor Lesions in Countries With Differential Gastric Cancer Burden: A Systematic Review and Meta-analysis	76
Blue Notes	76
Association Between Index Adenomas and Advanced Findings at Third Colonoscopy: Data From the New Hampshire Colonoscopy Registry	75
The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease	75
Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy	74

Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial	73
Table of Contents	71
Update in the Treatment of the Complications of Cirrhosis	71
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis	71
Reply	69
Blue Notes	69
Editorial Board	69
Front Cover	68
Continuing the Commitment to Diversity, Equity, and Inclusion Within AGA Journals	67
Acute-onset Type 1 Diabetes Mellitus and Pancreatic Atrophy Caused by an Immune Checkpoint Inhibitor	67
Response to “Recent Advancements and Future Perspectives of Per Oral Endoscopic Myotomy”	66
Reply	65
Multiple Negative Fecal Immunochemical Tests: Is Testing Really Better?	65
Reply	65
Needle Track Seeding After Trans-gastric EUS-guided Tissue Sampling: Maybe Not as Rare as You Think	65
Low Colorectal Cancer Risk After Resection of High-Risk Pedunculated Polyps	65
Hurdles in ERCP Trials: Do We Need to Change the Diagnostic Criteria for Post-ERCP Pancreatitis?	64
Upadacitinib in Mothers With Inflammatory Bowel Disease: Placental Transfer and Breast Milk Excretion	64
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease	63
Value of Ammonia Testing in Clinical Practice	63
Preoperative Hepatology and Primary Care Visits Improve Postoperative Outcomes in Patients With Cirrhosis Undergoing Surgery	63
A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis	63
The New Kids on the Block: Emerging Complementary Colonoscopy Quality Metrics	62
Editorial Board	62
Direct Oral Anticoagulants in Budd-Chiari Syndrome: Need a Closer Look!	62
Editorial Board	61
Von Willebrand Factor Level Indicate Response to β-Blockers in Cirrhosis: Need a Closer Look!	61
Reply	61
Reply	61
Transient Uterine Prolapse: A Rare Complication of Endoscopic Polypectomy	60
Foaming at the Varix: Sclerotherapy of Esophageal Varices via Intrahepatic Portal Vein Access	60
Cover	60
A Framework for Creating a FOAMed Organization in Gastroenterology: Lessons Learned from the Liver Fellow Network	60
Reply	60
Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey	59
Statins for Chronic Liver Disease and the Need for Randomized Controlled Trials	59
Cover	59
Environmental Toxins in Breast Milk and Risk of Early Onset Colorectal Cancer	58
Clinical Outcomes of Intraductal Papillary Mucinous Neoplasms With Dilatation of the Main Pancreatic Duct	58
Reply	58
North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process	58
Mental Health Diseases Are Associated With Active Hepatitis C and Partly Drive Hepatocellular Carcinoma Trends in Veterans	57
Gastroparesis and Chronic Pancreatitis: Are They Truly Related?	57
Adenoma Detection Rate and Clinical Characteristics Influence Advanced Neoplasia Risk After Colorectal Polypectomy	56
Skills or Pills: Randomized Trial Comparing Hypnotherapy to Medical Treatment in Children With Functional Nausea	56
All-cause and Cause-specific Mortality in Achalasia: A Nationwide Matched Cohort Study	56
Constrictive and Hypertrophic Strictures in Ileal Crohn’s Disease	56
Uptake of Colorectal Cancer Screening in 45 to 49 Year Olds: An Early-Inning View from the Endoscopy Suite	56
Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations	55
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19	54
Reply	54
Long-Term Outcomes After Endoscopic Submucosal Dissection for T1 Colorectal Cancer: A Multicenter Prospective Study	54
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease	54
From Onboarding to Excellence: Creating Gastroenterology Advanced Practice Provider Fellowship Programs That Benefit Practices, Patient Access, and Specialty Growth	54
Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network	54
Risk of Advanced Colorectal Neoplasia at Follow-up Colonoscopy After Synchronous Adenoma and Clinically Significant Serrated Polyp	53
Harm-to-Benefit Ratio of Fecal Immunochemical Test–Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations	53
Significance of Crypt Atypia in Barrett’s Esophagus: A Clinical, Molecular, and Outcome Study	52
The Affordable Care Act Improves Access, Survival, and Racial Disparities of Patients With Liver Disease: A Systematic Review	52
Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges	52
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn’s Disease	51
Real-world Comparison of Steatosis-Associated Fibrosis Estimator and Fibrosis-4 Scores for Assessing Metabolic Dysfunction-associated Steatotic Liver Disease-related Fibrosis in a Highly Diverse Urban	51
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update	51
Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes	50
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma	50
Bouveret Syndrome Treated With Endoscopic Lithotripsy and Gallbladder Access via Cholecysto-duodenal Fistula	49
The Severity of Reduced Esophageal Distensibility Parallels Eosinophilic Esophagitis Disease Duration	49
Assessing Diagnostic Performance of Modifications to the Rome IV Criteria for Irritable Bowel Syndrome	49
Correction	49
Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies	49
Diet and Microbiome-Directed Therapy 2.0 for IBD	49
Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease	48
Extraintestinal Symptoms in Irritable Bowel Syndrome Are Associated With Stress Reactivity and the Gut Microbiome in a Sex-dependent Manner	48
An Unusual Complication of Endoscopic Ultrasound-Guided Transgastric Liver Biopsy	47
Perianal Fistulizing Crohn’s Disease–Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus	47
Diverticulosis Is Associated With Internal Hemorrhoids on Colonoscopy: Possible Clues to Etiology	47
Distinctive Clinical Correlates of Small Intestinal Bacterial Overgrowth with Methanogens	47
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion	47
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis	47
Upadacitinib achieved rapid response in biologic-refractory immune checkpoint inhibitor-related enterocolitis	47

Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s Disease	47
Colon Volume by Computed Tomography and Scintigraphic Colonic Transit in Constipated Patients With or Without Redundant Colon	47
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis	46
Population-based Screening for Hereditary Colorectal Cancer Variants in Japan	46
Birth Cohort Colorectal Cancer (CRC): Implications for Research and Practice	46
Development of a Practical Guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis	46
Reply	46
Approach to Dietary Restriction in Irritable Bowel Syndrome	45
Front Cover	45
Nature and Nurture in Familial Aggregation of Steatotic Liver Disease	45
Editorial Board	45
Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma With Varices Using Red Dichromatic Imaging	45
Editorial Board	45
Blue Notes	44
Repeating Ultrasound for Hepatocellular Carcinoma Detection in Case of Inadequate Liver Visualization: A Matter of Expertise	44
Reply	44
Reply	44
Reply	44
Adult-Onset Fontan Circuit Failure: A Rare Cause of Protein-Losing Enteropathy	44
Front Cover	43
Reply	43
Reply	43
Editorial Board	43
Disparities in Colorectal Cancer Screening Among Asian American Populations and Strategies to Address These Disparities	43
Information for Authors and Readers	43
Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C	42
Editorial Board	42
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease	42
Elsewhere in the AGA Journals	42
Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study	42
To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn’s Disease	42
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases	42
Blue Notes	42
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease	42
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat	42
Letter Response to: Hernandez-Rocha C et al, Clin Gastroenterol Hepatol 2024	41
Gastric Emptying, Colon Filling, and Multiregional Gut Transit Delays Are Prevalent on Glucagon-Like Peptide-1 Agonists	41
Elsewhere in the AGA Journals	41
Ustekinumab and Vedolizumab Safety and Clearance in Pregnancy With Inflammatory Bowel Disease: Stop the Disease, Not the Drug!	41
Diffuse Large B-Cell Duodenal Lymphoma Presenting With Obstruction and Pneumatosis	41
Preparing the Next Generation of Gastroenterologists to Tackle Climate Change	41
Prediction of Postoperative Recurrence in Crohn’s Disease: Where Do We Go From Here?	41
Reply	40
AGA Clinical Practice Update on Endoscopic Lifting Agents: Commentary	40
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease	40
Dietary Fiber is Associated With Decreased Risk of Gastroesophageal Reflux Symptoms	40
Stratifying Risks of Ileal Pouch Outcomes	40
Is Baseline Metabolic Dysfunction-associated Steatohepatitis Fibrosis the Key Determinant for Survival After Bariatric Surgery?	40
Reply	40
Declines in Colorectal Cancer Incidence and Mortality Rates Slow Among Older Adults	39
Endoscopic Sedation Type During FLIP Panometry Does Not Significantly Impact FLIP Motility Classification Relative to Manometry	39
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis	39
Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era	39
Crafting a Therapeutic Pyramid for Eosinophilic Esophagitis in the Age of Biologics	39
Linked-Color Imaging Detects More Colorectal Adenoma and Serrated Lesions: An International Randomized Controlled Trial	39
Symptom Classes in Decompensated Liver Disease	39
Internal Hernia and Volvulus After Endoscopic Ultrasound-guided Gastrojejunostomy	39
Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance	39
Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis	39
Abdomino-anal Dyscoordination in Defecatory Disorders	39
Lymphangioma in a Child Managed With Debulking Surgery	39
Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL Study	39
Unaddressed Limitations of Alanine Aminotransferase as a Screening Tool for Pediatric Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease	38
Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis	38
Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet	38
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis	38
Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation	38
Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999–2018	38
Baseline Hepatitis B Virus Surface Antigen Titers in Childhood Predict the Risk of Advanced Liver Fibrosis in Adulthood	38
Knowledge, Attitudes, and Environment Related to Gastroenterology and Hepatology Care for Sexual and Gender Minorities	38
Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn’s Disease in the CELEST Extension Study	38
Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: A TOpClass Global Expert Delphi Consensus	37
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice	37
Reply	37
Antibiotic Use and Later Risk of Celiac Disease: A Nationwide Case-Control and Sibling Analysis	37
Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease	37
Perceptions, Definitions, and Therapeutic Interventions for Occasional Constipation: A Rome Working Group Consensus Document	37
Establishing an Endobariatric Practice: Steps, Challenges, and Considerations Within a Private Practice Model	37
Interventional Radiological Management for Budd-Chiari Syndrome: A 10-Year Retrospective, Multicenter Survey on 997 Patients in China	36
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects	36
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study	36
Impact of Chronic Hepatitis B and Its Clinical Phases on Liver Fibrosis and Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease	36
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction–associated Steatotic Liver Disease in Clinical Practice	36
Table of Contents	36
Supplementing Dietary Fibers With a Low FODMAP Diet in Irritable Bowel Syndrome: A Randomized Controlled Crossover Trial	35
Elsewhere in the AGA Journals	35
Reply	35
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis	35
Elsewhere in the AGA Journals	35
Editorial Board	35
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis	35
Missed Opportunity to Triage Patients With Irritable Bowel Syndrome to Multidisciplinary Therapy	35
Population-Attributable Fractions of Nonalcoholic Fatty Liver Disease on All-Cause and Cause-Specific Mortality Risk: How Large is the Impact?	35
Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn’s Disease but Not in Ulcerative Colitis	34
Clinical Characteristics and Treatment Outcomes in Patients With Incomplete Microscopic Colitis: Consideration for Expanding the Definition of Microscopic Colitis	34